Validity of serum galectin-4(Gal-4) in diagnosis of gastric adenocarcinoma:

Aida R. Al-Derzi *  MBChB, MSc, FICMs/Path
Hind H. Al-Ammiri**  BVM&S, MSC, IMMUNOLOGY
Nahla Ghanim***  MBChB, FICMS/ Path

Abstract:

Background: Galectin-4 is one of a b-galactosides binding proteins family that recognize a variety of glycan-containing proteins at the cell surface and are overexpressed in various tumors, including gastric cancer. Galectin-4 overexpression as well as changes in their subcellular distribution has been associated with gastric cancer progression and poor prognosis. It may provide diagnostic molecular markers for gastric cancer as well as clues for developing therapeutic targets on individual basis.

Objectives: The aims of the present study were to determine the levels of GAL-4 in the sera of healthy people and patients with gastric cancer and also, to investigate the validity of using GAL-4 as a specific diagnostic marker of gastric cancer.

Patients and methods: Twenty five gastric cancer patients were included in this study. They were among patients who attending the Endoscopy Department in Baghdad Medical City Teaching Hospital, during the period from December 2011 to July 2012. In addition, fifteen apparently healthy person were chosen as a healthy control group. For these two groups, serum level of GAL-4 using sandwich ELISA technique was carried out.

Results: There was a statistically significant difference in serum level of GAL-4 among gastric adenocarcinoma patients in comparison to healthy controls (p≤0.001), using receiver operating characteristic curve (ROC) area, serum GAL-4 has high area under the curve (0.924) with a cut off value equal to or above 0.42ng/ml which was associated with the highest sensitivity (100%).

Conclusions: The current study showed that serum levels of GAL-4 were significantly higher in patients with malignant gastric adenocarcinoma which may confirm a possible role of this marker in the pathogenesis of the disease, furthermore the highest sensitivity and best accuracy obtained from serum GAL-4 was by using a cut off values equal to or above 0.42ng/ml; Therefore, GAL-4 may be promising new diagnostic tools especially at early stages and among patients at high risk.

Key words: galectin-4, gastric cancer, validity.

Introduction:

Gastric cancers are one of the most frequent fatal malignancies in the world (1) and have a wide pathological and biological variety (2). However, accurate molecular pathways of gastric carcinogenesis and clinical progression are yet to be elucidated. So that, a comprehensive proteins expression profile of gastric cancers is necessary to provide a diagnostic molecular markers for gastric cancer as well as to clue for developing therapeutic targets on individual basis (3). Despite a major decline in incidence and mortality over several decades, stomach cancer is still has a 10-fold variation in incidence between populations at the highest and lowest risk. The incidence is particularly high in East Asia, Eastern Europe, and parts of Central and South America, and it is about twice as high among men than among women; It is estimated about 21,600 men and women (13,230 men and 8,370 women) will be diagnosed with it and 10,990 men and women will die from gastric cancer in 2013(4,5). Galectins are a group of proteins that bind β-galactosides through evolutionarily conserved sequence elements of the carbohydrate recognition domain (CRD) (6, 7, 8). As galectins are expressed by different immune and inflammatory cells, therefore, they can affect and regulate different responses produced by the host against tumors. In addition, galectins are released by tumors and can modulate a variety of inflammatory responses (9, 10) either by amplification of the inflammatory responses, including regulation of leukocyte survival and function or activation of homeostatic signals to shut off immune effector functions. Like many other cytokines and growth factors, galectins may exhibit a ‘double-edge sword’ effect depending on many different intrinsic factors like microenvironment (11, 12). Furthermore some galectins released by the tumor might help the tumor to evade the immune surveillance (13).
Patients and methods:
A total of 25 cases with gastric cancer were included in the study. Their age ranged between 34 to 77 years with a mean of 60.4 +/- 10.7 years (+/-SD). On the other hand a total of 15 healthy controls were included in the study. Their age ranged between 32 to 76 years with a mean of 53.6 +/- 10.9 years (+/-SD). Those patients were diagnosed clinically, radiologically, cytologically, and histopathologically by specialists, they were among patients who attending the Endoscopy Department Bagdad Medical City Teaching Hospital, during the period from December 2011 to July 2012. Also, fifteen apparently healthy person were chosen as a healthy control group. For these two groups, serum level of GAL-4 using sandwich ELISA technique was carried out.

Kits and reagents:
Galectin-4 (Gal-4) ELISA KIT (Antibodies-Online.Com): The kit was a sandwich enzyme immunoassay for in vitro quantitative measurement of GAL-4 in human serum, plasma & other biological fluids (14).

Statistical analysis:
Statistical analysis was done using SPSS version 20 computer software (Statistical Package for Social Sciences). The majority of the outcome quantitative variables were non-normally distributed. Such variables are described by median and interquartile range. Statistical significance of differences between averages for parameters of normal distribution was assessed using the Student’s t-test, and the difference in median of a quantitative non-normally distributed variable between 2 groups was assessed by nonparametric Mann-Whitney test. The statistical significance, direction and strength of linear correlation between 2 quantitative variables, one of which being non-normally distributed was measured by Spearman’s rank linear correlation coefficient. P value less than the 0.05 level of significance was considered statistically significant (15).

Results:
The ranges, median and mean value of serum GAL-4 in blood of gastric cancer patient and control groups are shown in table 1; there was a statically significant difference in the serum level of GAL-4 between gastric adenocarcinoma patients and healthy controls (p < 0.001), as shown in (table 1 and figure 1).

Table 1: the ranges, median and mean values of serum GAL-4 in blood of gastric cancer patients and control groups.

<table>
<thead>
<tr>
<th>Serum Galectin-4</th>
<th>Case-control comparison</th>
<th>N</th>
<th>Range</th>
<th>Median</th>
<th>Mean rank</th>
<th>Interquartile range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>15</td>
<td>0.50</td>
<td>(0.22 - 0.7)</td>
<td>9.90</td>
<td>(0.28 - 0.61)</td>
<td></td>
</tr>
<tr>
<td>Cases (Gastric AdenoCarcinoma)</td>
<td>25</td>
<td>2.97</td>
<td>(0.46 - 41.41)</td>
<td>26.86</td>
<td>(0.85 - 16.96)</td>
<td></td>
</tr>
</tbody>
</table>

P (Mann-Whitney < 0.001)

Figure 1: differences in median values of serum GAL-4 between 2 study groups.
The cut-off value of serum GAL-4 associated with highest (perfect) sensitivity (100%) was equal to or above 0.42 ng/ml. Testing negative at this cut-off value (serum level < 0.42 ng/ml) would exclude a possible diagnosis of gastric adenocarcinoma with 100% confidence (NPV = 100%). The cut-off value associated with highest specificity (100%) was set at equal to or above 2.07 ng/ml. this cut-off value has an average sensitivity (56%). Testing positive at this high cut-off value (obtaining a serum GAL-4 concentration of 2.07 and above ng/ml) would establish a diagnosis of gastric adenocarcinoma in any clinical context (any pretest probability). The optimum cut-off value of serum GAL-4 in the context of case-control differentiation is the cut-off value that can classify tested subjects into gastric adenocarcinoma...
Validity of serum galectin-4 (Gal-4) in diagnosis of gastric adenocarcinoma: Aida R. Al-Derzi

Discussion:
The current study showed that the median serum GAL-4 was significantly higher among gastric cancer patients in comparison to healthy controls (p < 0.001). These findings were in agreement with a study conducted by Barrow et al. (2011) who reported that the concentrations of free circulating galectins-2, -3, -4, and -8 were all markedly increased in the blood circulation of patients with gastrointestinal tract cancer and, in particular, those with metastasis. The presence of these galectins promotes cancer cell adhesion to vascular endothelial cells by interaction with the Thomsen-Friedenreich (TF) disaccharide on cancer associated mucin protein-1 (MUC1) (16). Furthermore, a series of experimental and clinical data demonstrated a correlation between galectins expression and tumor progression and metastasis. Galectins function inside the cells in both carbohydrate dependent and in dependent manners and can regulate signal transduction as well as epithelial morphogenesis via an effect on centrosome biology (17). In this study, serum GAL-4 was associated with high validity when used as a predictor test for advanced gastric adenocarcinoma. The high validity is evident from the large area under the ROC curve (0.924) which is significantly higher than (0.5) area associated with an equivocal test. In order to study the validity of serum GAL-4 in differentiating between gastric cancer patients from healthy controls, the present study showed that in a patient with serum GAL-4 equal to or above 0.42 ng/ml (cut off value) one can establish the diagnosis of gastric cancer with 62.5% confidence (PPV) in a clinical context, when gastric cancer is highly unlikely on clinical bases (pretest probability is 10% only) Testing positive at the optimum cut-off value would establish the diagnosis of gastric adenocarcinoma with 82% confidence in a clinical context of equal odds pretest probability for gastric adenocarcinoma; when the pretest probability of having this disease is increased to 90% (high clinical suspicion) having a positive test would be almost diagnosis raising the confidence in the diagnosis of gastric malignancy to 97.6%. The mechanism for the increased circulating galectins in patients with gastric cancer is unclear. Members of galectins family are expressed by many types of human cells including epithelial, endothelial and immune cells including monocyte, macrophage and lymphocytes (16). The expressions of galectins in immune cells are heavily influenced by inflammatory regulator and also by differentiation and activation (18, 19). Many proinflammatory cytokines including TNF-α, IL-1, IL-8, and GM-CSF are up regulated in cancerous conditions and their presences may cause the immune cells to secrete more galectins in the blood stream (16, 20).

Finally, targeting the actions of circulating galectins in the bloodstream of gastric cancer patients may represents a very promising therapeutic strategy for preventing metastasis (21).

Authors’ contribution:
- Aida R. Al-Derzi / study conception, design, data analysis & critical revision.
- Hind H. Al-Ammiri / study conception, data collection & analysis design and interpretation of results.
- Nahla Ghanim / acquisition of data analysis and critical revision.

References:
Validity of serum galectin-4 (Gal-4) in diagnosis of gastric adenocarcinoma: Aida R. Al-Derzi


